MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-12-2026
Check-Cap Ltd. Retained Earnings 2011-2026 | CHEK
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Check-Cap Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -166 M | -170 M | -145 M | -127 M | -108 M | -91 M | -77.1 M | -63.3 M | -52.7 M | -42.9 M | -34.1 M | -26.6 M | -22.5 M | -18.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.5 M | -170 M | -81.8 M |
Quarterly Retained Earnings Check-Cap Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -166 M | -165 M | -170 M | -151 M | -145 M | -139 M | - | - | - | - | -108 M | - | -98.5 M | - | -91 M | - | -83.5 M | - | -77.1 M | - | -69.8 M | - | -63.3 M | - | -57.5 M | - | -52.7 M | - | -48.4 M | - | -42.9 M | - | -38.8 M | - | -34.1 M | - | - | - | -21.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -21.8 M | -170 M | -91.2 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.32 | -19.18 % | $ 1.76 M |  USA |
 |
Agilent Technologies
A
|
348 M | $ 112.44 | -0.71 % | $ 34.2 B | USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 19.2 | 1.69 % | $ 557 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.88 | -1.91 % | $ 480 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 140.85 | -1.67 % | $ 22.4 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.8 | - | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 19.88 | -2.98 % | $ 1.06 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 94.55 | -2.2 % | $ 6.38 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 419.78 | 0.15 % | $ 12.1 B | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 051.07 | 0.88 % | $ 21.7 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 3.65 | 0.69 % | $ 338 M | USA |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
NeoGenomics
NEO
|
-434 M | $ 8.32 | -0.54 % | $ 1.07 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 18.64 | -1.53 % | $ 417 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 188.14 | -4.45 % | $ 18.5 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 155.97 | -1.98 % | $ 7.73 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 93.95 | -4.77 % | $ 11.8 B | USA |
 |
Personalis
PSNL
|
-631 M | $ 6.56 | -2.24 % | $ 585 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 5.71 | -1.89 % | $ 238 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 118.48 | 1.19 % | $ 9.77 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
-431 M | $ 52.98 | -0.02 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.36 | -2.07 % | $ 5.42 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 252.76 | -0.5 % | $ 21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | - | - | $ 167 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.56 | -3.75 % | $ 201 M | Irlanda |
 |
Celcuity
CELC
|
-449 M | $ 134.53 | -0.14 % | $ 6.29 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K |  Israel |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 48.6 | -8.22 % | $ 2.91 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 8.32 | -1.25 % | $ 1.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 187.2 | -0.39 % | $ 20.8 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |